PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) was the first prospective, international, multicenter, natural history study using 3-vessel multimodality intracoronary imaging to quantify the clinical event rate due to atherosclerotic progression and to identify those lesions which place patients at risk for unexpected adverse cardiovascular events. This landmark study of 700 Acute Coronary Syndrome (ACS) patients was co-funded by Volcano and utilized Volcano's proprietary VH^® IVUS technology to classify lesions by plaque type. Three-year clinical event data was presented by Dr. Gregg Stone of Columbia University Medical Center on September 24, 2009 at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, CA.

View Press Release (PDF)

IBIS II Study

Integrated Biomarker Imaging Study 2 was a one year, 300 participant, international, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of darapladib in subjects with angiographically documented coronary heart disease. The study's main objectives were to determine the effects of darapladib on composition and biomechanical properties of atherosclerotic plaque, as well as circulating inflammatory biomarkers. Glaxo Smith Kline was the sponsor of the study. Volcanos grayscale IVUS and VH^® IVUS derived key vessel volumes and measurements from baseline and at one year follow up. Results of this study were presented on September 2, 2008 at the European Society of Cardiologists (ESC) in Munich, Germany.

View Press Release (PDF)